April 28, 2011
– Comments (1)
a post from April 2010.
it still works ...
Score: +4,055.12Accuracy: 80.32%
Score: +4,144.15Accuracy: 61.94%
a few posts by zzlangerhans.
Small cap biotech investing in the era of underperformance
Biotech investing - the Good, the Bad, and the Ugly
Biotech Investing: The Ugly
Ugly lessons in Biotech: Pay attention to interim data from phase III trials
Ugly lessons in biotech: Avoid binary events
Ten Rules of Small Cap Biotech Investing: Lessons From the Ugly
Small cap biotech: The BAD (part I)
Small cap biotech: The BAD (part II)
Small cap biotech: The GOOD (part I)
Small cap biotech: The GOOD (part II)
Small cap biotech: the GOOD (part III)
A question from an Idiot about the S&P comparison
Efficient market? Not in Biotech.
GOOD and BAD Biotechs: One year later
GOOD and BAD Biotechs: One year later (part II)
GOOD and BAD Biotechs: One year later (part III)
Grabbing Bottoms in Miami Beach: A Trader's Manifesto
Two bottoms and a put
Two new bottoms for the GBMB
Two more bottoms for the GBMB
Back in the GBMB hunt
More bottoms for the grabbing
The GBMB in review, part I
The GBMB in review, part II
The GBMB in review, part III
and don't listen to "caps" game players that use book value and revenue of development stage "baby biotech" companies as their primary guideline, hehe (just kidding) ...
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by